Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Interventions

pembrolizumab 210 Cyclophosphamide 122 Nivolumab 109 Carboplatin 92 fludarabine 81 Gemcitabine 76 Specimen Handling 74 Bevacizumab 72 venetoclax 70 Injections 70 Magnetic Resonance Spectroscopy 67 Dexamethasone 66 Paclitaxel 64 Biopsy 59 atezolizumab 56 Cisplatin 53 Ipilimumab 50 Temozolomide 45 Docetaxel 42 Azacitidine 42 Pemetrexed 41 Lenalidomide 41 Oxaliplatin 40 Rituximab 39 Radiotherapy 39 Fluorouracil 39 Cetuximab 37 durvalumab 36 Cytarabine 36 Capecitabine 36

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Lamivudine × 1 year × Clear all

NCT06494579 2025-12-16

Lamivudine for Solid Tumors

Icahn School of Medicine at Mount Sinai

Phase 1/2 Active not recruiting

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡